ProQR Therapeutics N.V. (PRQR) EPS Estimated At $-0.46; Molina Healthcare (MOH) Has 1.28 Sentiment

April 12, 2018 - By Richard Conner

Molina Healthcare, Inc. (NYSE:MOH) Logo

Analysts expect ProQR Therapeutics N.V. (NASDAQ:PRQR) to report $-0.46 EPS on May, 16.They anticipate $0.02 EPS change or 4.17% from last quarter’s $-0.48 EPS. After having $-0.46 EPS previously, ProQR Therapeutics N.V.’s analysts see 0.00% EPS growth. The stock increased 3.03% or $0.1 during the last trading session, reaching $3.4. About 81,330 shares traded. ProQR Therapeutics N.V. (NASDAQ:PRQR) has declined 31.52% since April 12, 2017 and is downtrending. It has underperformed by 43.07% the S&P500.

Molina Healthcare Inc (MOH) investors sentiment increased to 1.28 in 2017 Q4. It’s up 0.20, from 1.08 in 2017Q3. The ratio improved, as 122 institutional investors opened new and increased stock positions, while 95 decreased and sold equity positions in Molina Healthcare Inc. The institutional investors in our database now own: 61.86 million shares, up from 58.60 million shares in 2017Q3. Also, the number of institutional investors holding Molina Healthcare Inc in top ten stock positions increased from 1 to 2 for an increase of 1. Sold All: 19 Reduced: 76 Increased: 73 New Position: 49.

Analysts await Molina Healthcare, Inc. (NYSE:MOH) to report earnings on May, 1. They expect $0.84 earnings per share, down 42.86% or $0.63 from last year’s $1.47 per share. MOH’s profit will be $50.37 million for 24.23 P/E if the $0.84 EPS becomes a reality. After $0.34 actual earnings per share reported by Molina Healthcare, Inc. for the previous quarter, Wall Street now forecasts 147.06% EPS growth.

Ratings analysis reveals 17% of Molina Healthcare’s analysts are positive. Out of 6 Wall Street analysts rating Molina Healthcare, 1 give it “Buy”, 1 “Sell” rating, while 4 recommend “Hold”. The lowest target is $45.0 while the high is $52.0. The stock’s average target of $48.50 is -40.43% below today’s ($81.42) share price. MOH was included in 6 notes of analysts from September 19, 2016. The stock of Molina Healthcare, Inc. (NYSE:MOH) earned “Overweight” rating by Piper Jaffray on Wednesday, January 4. As per Thursday, February 16, the company rating was downgraded by Stifel Nicolaus. The firm earned “Underperform” rating on Friday, November 11 by Credit Suisse. The company was initiated on Wednesday, April 5 by Deutsche Bank. The stock of Molina Healthcare, Inc. (NYSE:MOH) earned “Neutral” rating by Goldman Sachs on Monday, September 19. The firm earned “Hold” rating on Thursday, December 15 by Jefferies.

Since January 1, 0001, it had 0 buys, and 20 selling transactions for $37.57 million activity.

The stock increased 0.88% or $0.71 during the last trading session, reaching $81.42. About 451,382 shares traded. Molina Healthcare, Inc. (MOH) has risen 69.35% since April 12, 2017 and is uptrending. It has outperformed by 57.80% the S&P500.

Molina Healthcare, Inc. provides Medicaid-related solutions to meet the health care needs of low-income families and individuals; and to assist state agencies in their administration of the Medicaid program in the United States. The company has market cap of $4.88 billion. It operates through three divisions: Health Plans, Molina Medicaid Solutions, and Other. It currently has negative earnings. The Health Plans segment operates health plans in 12 states.

Tiedemann Wealth Management Llc holds 7.91% of its portfolio in Molina Healthcare, Inc. for 1.35 million shares. Southpoint Capital Advisors Lp owns 790,000 shares or 2.88% of their US portfolio. Moreover, Sivik Global Healthcare Llc has 2.85% invested in the company for 100,000 shares. The California-based Partner Fund Management L.P. has invested 2.14% in the stock. Rock Springs Capital Management Lp, a Maryland-based fund reported 567,000 shares.

Molina Healthcare, Inc. (NYSE:MOH) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: